Literature DB >> 3132218

Natural course of penicillamine nephropathy: a long term study of 33 patients.

C L Hall1, S Jawad, P R Harrison, J C MacKenzie, P A Bacon, P T Klouda, A G MacIver.   

Abstract

To elucidate the natural course of the nephropathy associated with penicillamine and thereby facilitate its clinical management 33 patients with rheumatoid arthritis who developed proteinuria during treatment with oral penicillamine were studied in detail throughout their renal illness. Renal biopsies were performed, and creatinine clearance and proteinuria were measured serially for 74 months (range 16-148 months). Fourteen patients developed proteinuria within six months after the start of treatment and 27 within 12 months. When treatment was stopped the proteinuria reached a median peak of 4.2 g/24 h (range 0.3-15.0 g/24 h) at one month (range 0-7 months) before resolving spontaneously by six months (12 patients), 12 months (21), or 18 months (29). In all patients but one, who developed carcinoma of the renal pelvis, proteinuria resolved by 21 months and its median duration was eight months. The median first and last measurements of creatinine clearance showed no appreciable change (80 ml/min and 78 ml/min), and no patient died from or needed treatment for renal failure. The HLA-B8 or HLA-DR3 alloantigen, or both, were identified in 10 patients. Renal biopsy specimens showed membranous glomerulonephritis in 29 patients, minimal change nephropathy in two, and electron dense deposits in the mesangial regions in two. In all the patients whose nephropathy was due solely to treatment with penicillamine the proteinuria resolved completely when the drug was withdrawn; renal function did not deteriorate, and corticosteroids were unnecessary.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132218      PMCID: PMC2545495          DOI: 10.1136/bmj.296.6629.1083

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  15 in total

Review 1.  The management of cystinuria in 1976.

Authors:  A D Stephens
Journal:  Proc R Soc Med       Date:  1977

2.  Letter: Goodpasture syndrome and D-penicillamine.

Authors:  T Gibson; H C Burry; C Ogg
Journal:  Ann Intern Med       Date:  1976-01       Impact factor: 25.391

3.  Penicillamine in rheumatoid arthritis: clinical pharmacology and biochemical properties.

Authors:  I A Jaffe
Journal:  Scand J Rheumatol Suppl       Date:  1979

4.  Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study.

Authors:  P A Bacon; C R Tribe; J C Mackenzie; J Verrier-Jones; R H Cumming; B Amer
Journal:  Q J Med       Date:  1976-10

5.  Immunopathology of penicillamine-induced glomerular disease.

Authors:  F E Dische; D R Swinson; E B Hamilton; V Parsons
Journal:  J Rheumatol       Date:  1976-06       Impact factor: 4.666

6.  D-penicillamine and immune complex deposition.

Authors:  J D Kirby; P A Dieppe; E C Huskisson; B Smith
Journal:  Ann Rheum Dis       Date:  1979-08       Impact factor: 19.103

7.  Membranous nephropathy in patients with rheumatoid arthritis: relationship to gold therapy.

Authors:  B Samuels; J C Lee; E P Engleman; J Hopper
Journal:  Medicine (Baltimore)       Date:  1978-07       Impact factor: 1.889

8.  Penicillamine in rheumatoid disease: a long-term study.

Authors:  A T Day; J R Golding; P N Lee; A D Butterworth
Journal:  Br Med J       Date:  1974-02-02

9.  HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.

Authors:  P H Wooley; J Griffin; G S Panayi; J R Batchelor; K I Welsh; T J Gibson
Journal:  N Engl J Med       Date:  1980-08-07       Impact factor: 91.245

10.  Maintenance dose of penicillamine in rheumatoid arthritis: a comparison between a standard and a response-related flexible regimen.

Authors:  H F Hill; A G Hill; A T Day; R M Brown; J R Golding; W H Lyle
Journal:  Ann Rheum Dis       Date:  1979-10       Impact factor: 19.103

View more
  16 in total

Review 1.  Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis.

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Atsushi Hashimoto; Shigeto Tohma
Journal:  J Hum Genet       Date:  2015-04-23       Impact factor: 3.172

2.  Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease.

Authors:  Keiichi Sumida; Miklos Z Molnar; Praveen K Potukuchi; Fatima Hassan; Fridtjof Thomas; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Kidney Int       Date:  2018-03-02       Impact factor: 10.612

Review 3.  Clinical manifestations of Wilson disease in organs other than the liver and brain.

Authors:  Karolina Dzieżyc-Jaworska; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

4.  A prospective study of renal disease in patients with early rheumatoid arthritis.

Authors:  Y Koseki; C Terai; M Moriguchi; M Uesato; N Kamatani
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

5.  Determination of IgA- and IgM-rheumatoid factors in patients with rheumatoid arthritis with and without nephropathy.

Authors:  M Nakano; M Ueno; S Nishi; S Suzuki; H Hasegawa; T Watanabe; T Kuroda; S Ito; M Arakawa
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

Review 6.  The optimum management of arthropathies.

Authors:  C S Wolfe; G R Hughes
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

7.  Management of proteinuria secondary to penicillamine therapy in rheumatoid arthritis.

Authors:  R N DeSilva; C J Eastmond
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

Review 8.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

Review 9.  Urolithiasis in children: current medical management.

Authors:  J Laufer; H Boichis
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

10.  Development of reduced kidney function in rheumatoid arthritis.

Authors:  LaTonya J Hickson; Cynthia S Crowson; Sherine E Gabriel; James T McCarthy; Eric L Matteson
Journal:  Am J Kidney Dis       Date:  2013-10-04       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.